Vnitr Lek 2015, 61(Suppl 4):6-12

Approach to patients with liver diseases

Radan Brůha
IV. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Aleš Žák, DrSc.

In recent years the most frequent cause of chronic liver diseases in western countries has become Non-alcoholic hepatic steatosis/steatohepatitis (NAFLD/NASH). It is part or immediate manifestation of metabolic syndrome. A crucial task for the future is to diagnose this hepatic injury to a greater extent and cooperate with other internal medicine physicians in the care of patients with NAFLD. It has been clearly proven that it is not a benign disease, as assumed in the past. Non-alcoholic steatohepatitis can have serious consequences for the patient and it needs to be actively searched for. The still prevalent notion that normal liver tests in patients with hepatic steatosis eliminate a more serious liver injury has also been disproved. On the contrary, this condition is common in patients with NAFLD. Also the patients with normal liver test results can have advanced fibrosis/cirrhosis. It is needed to target identification of a liver injury in a patient with the detected metabolic syndrome with the same intensity as the other diabetes complications are searched for today. All patients with type 2 diabetes mellitus (DM2T) should undergo ultrasound examination of the liver and it is further recommended to check the liver tests in annual intervals at least. The cause of liver lesions should be found in all diabetics who had higher liver test values established even once. The liver injury needs to be further regularly followed in these patients. Regarding the patients without the metabolic syndrome anamnesis with the NAFLD signs, it is needed to actively search for the components of the metabolic syndrome (hypertension, dyslipidemia, impaired glucose tolerance, diabetes).

Keywords: alcoholic liver injury; cirrhosis; liver fibrosis; metabolic syndrome; NAFLD; non-alcoholic hepatic steatosis

Received: November 9, 2015; Published: August 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brůha R. Approach to patients with liver diseases. Vnitr Lek. 2015;61(Supplementum 4):6-12.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58(3): 593-608. Go to original source... Go to PubMed...
    2. Kim HC, Nam CM, Jee SH et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328(7446): 983. Go to original source... Go to PubMed...
    3. Ehrmann J, Hůlek P (eds) et al. Hepatologie. Grada Publishing: Praha 2010. 616 s. ISBN 978-80-247-3118-6. 4.
    4. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36(3): 437-441. Go to original source... Go to PubMed...
    5. Wieckowska A, Mc Cullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46(2): 582-589. Go to original source... Go to PubMed...
    6. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29(12): 1705-1713. Go to original source... Go to PubMed...
    7. Rifai K, Cornberg J, Mederacke I et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis 2011; 43(6): 491-497. Go to original source... Go to PubMed...
    8. Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60(7): 977-984. Go to original source... Go to PubMed...
    9. Poynard T, Lebray P, Ingiliz P et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40. Dostupné z DOI: <http://doi:10.1186/1471-230X-10-40>. Go to original source... Go to PubMed...
    10. Zatonski WA, Sulkowska U, Manczuk M et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16(4): 193-201. Go to original source... Go to PubMed...
    11. Bosetti C, Levi F, Lucchini F et al. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46(5): 827-839. Go to original source... Go to PubMed...
    12. Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41(6): 845-850. Go to original source... Go to PubMed...
    13. Snow WM, Murray R, Ekuma O et al. Alcohol use and cardiovascular health outcomes: a comparison across age and gender in the Winnipeg Health and Drinking Survey Cohort. Age Ageing 2009; 38(2): 206-212. Go to original source... Go to PubMed...
    14. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36(3): 242-252. Go to original source... Go to PubMed...
    15. Raynard B, Balian A, Fallik D et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35(3): 635-638. Go to original source... Go to PubMed...
    16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16): 1221-1231. Go to original source... Go to PubMed...
    17. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(3): 917-923. Go to original source... Go to PubMed...
    18. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35(2): 373-379. Go to original source... Go to PubMed...
    19. Tuyama AC, Chang CY. Non-alcoholic fatty liver disease. J Diabetes 2012; 4(3): 266-280. Go to original source... Go to PubMed...
    20. Bellentani S, Bedogni G, Miglioli L et al. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16(11): 1087-1093. Go to original source... Go to PubMed...
    21. Hilden M, Christoffersen P, Juhl E et al. Liver histology in a "normal" population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12(5): 593-597. Go to original source... Go to PubMed...
    22. Dvorak K, Hainer R, Petrtyl J et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(3): 442-448. Go to original source... Go to PubMed...
    23. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129(1): 113-121. Go to original source... Go to PubMed...
    24. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 162-168. Go to original source... Go to PubMed...
    25. Baumeister SE, Völzke H, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134(1): 85-94. Go to original source... Go to PubMed...
    26. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147(4): 754-764. Go to original source... Go to PubMed...
    27. Haflidadottir S, Jonasson JG, Norland H et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166. Dostupné z DOI: <http://doi:10.1186/1471-230X-14-166>. Go to original source... Go to PubMed...
    28. Barrio E, Tome S, Rodriguez I et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28(1): 131-136. Go to original source... Go to PubMed...
    29. Reeves HL, Burt AD, Wood S et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25(6): 677-683. Go to original source... Go to PubMed...
    30. Teli MR, Day CP, Burt AD et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346(8981): 987-990. Go to original source... Go to PubMed...
    31. Ludwig J, Viggiano TR, Mc Gill DB et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-438. Go to original source...
    32. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(16): 1413-1419. Go to original source... Go to PubMed...
    33. Hultcrantz R, Glaumann H, Lindberg G et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21(1): 109-113. Go to original source... Go to PubMed...
    34. Pinto HC, Baptista A, Camilo ME et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41(1): 172-179. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.